




The appearance of Evidence Based Medicine (EBM) in the 1990’s (Sackett et al., 1996) 
heralded a transformation in health care practice. The growing evidence base from clinical 
trials, published in peer-reviewed medical journals, replaced unproven personal ideas and 
subjective experience as the foundation of health-related decisions. In the United 
Kingdom (UK), one response to this shift was the formation in 1999 of the National 
Institute for Clinical Excellence (NICE). Its aim was to make EBM tools and skills available 
to the UK’s National Health Service (NHS) in order to permit clinically and cost-effective 
health care (NICE, 2016). NICE produces clinical guidelines covering disease 
management and the effectiveness of interventions. In 2013 the name was changed to 
National Institute for Health and Care Excellence to reflect an extended remit covering 
the concepts of health promotion and social care (NICE, 2016). 
 
In health care, clinical guidelines are produced by multiple organisations at local, regional, 
national and international levels. They are recommendations to improve patient care, 
based on either systematic reviews of evidence, or consensus of expert opinions (Deng 
et al., 2016). Health care professionals often consider several different guidelines in 
informing their clinical decision making, with some proponents considering NICE clinical 
guidelines as the benchmark of best management (Streeter and Brewster, 2015). There 
are, however, concerns that injustice, prejudice and rationing are implicit in the guidelines 
(Harris, 2005). For example, advocates for certain patient-populations have previously 
considered NICE guidelines to be the UK government’s justification for withholding 
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expensive treatments, such as in Alzheimers disease (Hunt, 2007) and neuroblastomas 
in children (Bernstein, 2016) Others argue that the pre-digested evidence and ready-
made guidelines deskill clinicians (Hutchison and Rogers, 2012).  
   
Clinical Guideline 140 (CG140), ‘Opioids in palliative care: safe and effective prescribing 
of strong opioids for pain in palliative care of adults’ (NICE 2012), was published in 2012 
and reviewed in 2016. This paper will use this guideline as a basis for exploring the 
positivist, empirical paradigms of EBM and NICE. It will argue that these are insufficient 
foundations for dealing with the complexities of pain and the decisions relating to better 
managing it. Finally, the advantages of broadening the paradigmatic approach to CG140, 




NICE clinical guidelines are developed using standard processes, with explanations of 
how decisions and recommendations are made (NICE, 2009). A Guideline Development 
Group is responsible for each guideline and structure their appraisal of evidence using 
tools such as the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) system. NICE introduced the GRADE system to encourage a fairer 
and more rigorous weighting of the evidence. It replaced the hierarchy of evidence, which 
involved scoring evidence on a scale of trustworthiness, or alternatively as expert opinion. 
Qualitative research and integrative reviews, encompassing both qualitative and 
quantitative data, have been recognised as credible sources of evidence by NICE (NICE, 
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2017). However, there appears to remain an ongoing greater respect for methods 
belonging higher in the hierarchy, such as systematic reviews of randomised controlled 
trials (Hutchison and Rogers, 2012).  
 
Clinical Guideline: Opioids in Palliative Care 
 
Pain is a common problem in populations with life-limiting illnesses, with over 50% of 
these patients experiencing pain (Moens et al., 2014). The World Health Organisation 
(WHO) considers pain management a global priority and promotes a three-step guide to 
providing effective pain relief in adults, with strong opioids, such as Morphine at step three 
(WHO, n.d.). CG140 is published by NICE to promote safe effective prescribing of these 
strong opioids for pain, cognisant of the barriers to prescribing, such as, legislative, 
patient and prescriber (Nguyen et al., 2013; Flemming, 2010). It, however, contains no 
definition of pain, the central concept of the guideline. 
 
The philosophical foundations of research 
 
There are two main ways, or ontologies, in which the world can be viewed. In one way, 
an objective reality exists, independent of people or situations. Research is able to 
discover this reality with ‘better’ research leading to a closer reflection of what that reality 
is. This view describes the ontology labelled ‘positivism’ (Bryman, 2012). In the second 
view, the idea of a single true reality is rejected and replaced with the idea of multiple 
realities co-existing at the same time, possibly in the same situation. These realities are 
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created or constructed by people, both the researcher and the researched. This is line 
with constructivism and interpretivism (Ellingson, 2009). NICE provides no declaration of 
its paradigmatic framework; however, this paper argues that NICE publications are 
founded on a positivist paradigm (Wilmot 2011). 
 
Controversies of CG140: Pain 
 
Pain is a subjective, socially constructed phenomenon, embedded in the cultural context, 
which can best be described through our interpretation of it (Best, 2007). Scientific 
positivist approaches are useful in researching the pathophysiology of pain, however 
there are challenges measuring its subjective nature. Pain may be interpreted as a 
message, full of meaning and significance, such as from a deity. It may also be viewed 
as a meaningless organic symptom to be avoided, a challenge to be surmounted, or 
relating to guilt or shame (Renqvist, 2015). Irrespective of how it is interpreted, pain 
remains a personalised, idiosyncratic phenomenon, difficult for positivist research to 
access and measure (Morris, 1991). Researchers employ reductionist methodologies to 
measure pain, although there is no consensus on the classification of pain in cancer 
related clinical trials with extensive use of heterogenous, non-validated methods of pain 
assessment (Haugen, 2010). The Cancer Pain Assessment and Classification System 
recommends that there should be at least four domains to pain assessment; pain 





The critical appraisal of studies in CG140 includes no mention of how pain is defined, and 
limited consideration of its measurement. Pain intensity and, occasionally, breakthrough 
pain are the only related outcomes recorded in the evidence tables (NICE, 2012, 
Appendix E). For example, the literature search for review question 2: ‘What is the most 
effective first-line opioid treatment in patients with advanced and progressive disease who 
require strong opioids?’ identified twenty-five empirical quantitative studies. The 
respective evidence table recorded that pain intensity was measured through 100mm 
visual analogue scales (n=9), 4-point Likert scales (n=6), or was not recorded (n=10) 
(NICE, 2012. Appendix E). The broad concept of pain is reduced to a single numerical 
score, ready for statistical analysis. The social, psychological, and spiritual elements of 
the experience of pain are ignored (Morrissey, 2011). There exists more holistic or 
descriptive pain scales, such as the Brief Pain Inventory, however these are absent from 
the included evidence. The included study by Arkinstall et al. (1989) did use the McGill-
Melzack Pain Questionnaire however used only the sub-index ‘Present Pain Intensity’. 
 
Controversies of CG140: Biases 
 
NICE makes provision for certain biases in the critical appraisal of the included individual 
studies; such as, considering whether participants were suitably randomised and how 
drop-outs were accounted for in the statistical analysis. This approach is employed in an 
attempt to provide a just solution for a target population. It is important and appropriate; 
however, it is limited to the level of the individual studies. It does not question whether 
there are higher-level biases which prevent the selected evidence base from providing a 
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just solution. For example, the exclusion of older participants or those with co-morbidities 
from clinical research (Kelly et al., 2015). Most of the studies accepted as evidence for 
the NICE guidelines on managing older persons with low back pain excluded those over 
70 years old, and very few reported how the effectiveness of therapies differed by age 
(Schild von Spannenberg et al., 2013)  
 
The funding of clinical trials by pharmaceutical companies is a further example of injustice 
within clinical research. Industry-influenced research agendas have resulted in much of 
the current clinical research focusing on patentable treatments such as drugs or drug 
delivery technologies (Rogers & Ballantyne, 2009). Furthermore, published industry-
sponsored research produces more pro-industry outcomes compared to publicly funded 
research (Bhandari et al., 2004). To counter this bias, NICE recommends an evaluation 
of the funding sources of research through its inclusion in the generic evidence tables 
(NICE, 2009). However, this item is absent from the evidence tables employed in CG140 
(NICE, 2012, Appendix E) and as such, there is no record that the source of funding was 
considered in the critical appraisal of evidence. One of the papers accepted as evidence 
was Davies et al. (2011) who researched nasal fentanyl delivered by a new patented drug 
delivery system (Watts and Smith, 2009). The authors declared financial ties with the 
researched product in the original research paper, however the Guideline Development 
Group made no mention of this bias, either in the GRADE profile summary (NICE, 2012, 
table 13, page 51) or the respective evidence table (NICE, 2012, Appendix E, table 5, 





Controversies of CG140: Is the positivist foundation appropriate for the subject 
matter? 
 
The construction of the CG140’s review questions highlights the value-driven 
assumptions and the ontological foundation. The following review question illustrates this, 
‘What information do patients with advanced and progressive disease who require strong 
opioids, or their carers, need to consent to opioid treatment, and monitor the effectiveness 
and side effects of the opioid?’ (NICE, 2012a, p. 11). This question is defined as 
‘qualitative’ and therefore evidence was restricted to qualitative studies. Qualitative 
research methods are an appropriate choice to understand participants feelings and fears 
at a deeper level (Bryman, 2012). These methods, such as focus group or in-depth 
interviews are commonly founded on constructivism, in which the perspectives of the 
research participants are regarded as equally valid and real, even if conflicting.  However, 
the review question is phrased in a closed way which implies that there exists a single 
answer, true for all patients and their families. This is in line with the underlying positivist 
framework, which we argue is not in harmony with the ethos behind much of qualitative 
research. An alternative, more open, question would be preferable; such as, ‘how do 
patients with advanced and progressive disease who require strong opioids, or their 
carers, perceive opioid treatment?’. This would better facilitate the inclusion of data on 
the perspective of the patient and their family, rather than that of the health care 





The place for alternative philosophies 
 
Pain is a complex subjective phenomenon, however there is no acknowledgement within 
CG140 of the limitations of quantitative measurements of health, which reduce rich 
descriptions to a single numerical score. This reductionist approach to knowledge 
creation is framed within the concept of value-free interpretation of research findings. This 
is a flawed concept as there is an unbridgeable chasm between evidence and theory, 
labelled the Gap Argument (Goldenberg, 2014). Rather than being free of values and 
prejudices, this gap is filled with cultural, social and political values, and it is this value-
ladened environment that functions as a lens through which knowledge is created 
(Goldenberg, 2006). These values influence, not only, how policy makers, researchers 
and clinicians interpret data, but also how data is created; which topics are researched, 
the choice of research questions, the selection of methods and the level of integration of 
the patients in research (Kelly et al., 2015).  
 
Patient-centred care is central to EBM (Sackett et al., 1996). For it to be practiced, the 
health care professional needs to journey to the patient’s world and understand their 
feelings, thoughts and ‘lifeworld’ experiences (Svenaeus, 2003: p.415). We suggest that 
research approaches aligned to constructionism are inherently complementary to this 
approach. The rejection of an objective reality, and the possibility of multiple co-existing 
realities validates individual patients’ views as being insightful and important. Patient-
centred care is acknowledged in the section on patient information and communication. 
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It is not, however, carried over to the other sections, which maintain a symptom or 
disease-centred approach. 
G140 could be enriched by this genre of research; encouraging individuality, broadening 
the evidence base and challenging the objectives of the guidelines (Greenhalgh et al., 
2015): 
1. Individuality versus generic population: NICE guidelines are designed to be applied at 
an individual patient level; however, this purpose can be over-shadowed by the 
population-based evidence. The individual prescriber should be encouraged to consider 
the best fit for the patient in front of them, rather than the right response. (Kotzee et al., 
2016) 
2. Evidence base: The patient’s lifeworld, their understanding and experience of illness 
are valid and important sources of evidence (Goldenberg, 2006).  
3. Goal: The central tenet of CG140 is the provision of pain relief in an empirical 
biomedical context, however the patient-centred goal of management is the reintegration 
of the patient into their own lifeworld (Goldenberg, 2006). Patients do not consider a 
reduction of their pain on a numerical rating scale as helpful. They are interested in 
whether their pain is sufficiently controlled so that they can perform their desired activities 
and maintain their relationships (Gibbons et al., 2013). This is suggested as a topic for 
further research in the NICE guidelines 173: Neuropathic pain – pharmacological 






Synthesis of research 
 
Integrative reviews allow both quantitative and qualitative research to be synthesised to 
give a better understanding of the researched topic. The integration of data from 
qualitative methods can go some way of making guidelines more patient-centred, while 
being clinically and cost-effective. Qualitative research should not be relegated to the 
‘qualitative’ question, rather its integration with quantitative data can facilitate a better 
understanding of the wider subject area. There are now established approaches for the 
systematic review of qualitative studies, and the synthesis of qualitative and quantitative 
research in integrative reviews _REF NEEDED_. However, the integration of qualitative 
research into the production of guidelines has been slower (Munoz-Plaza et al., 2016; 
Utens et al., 2016). In the present structure of CG140, such findings are limited to the 
section on information and communication. An alternative approach is the mapping of 
qualitative data onto guidelines’ recommendations (Flemming, 2010). An example of how 
a sample of findings from qualitative data cited in this article could map onto a 
recommendation from CG140 is presented in table 1.  
Author Recommendation 1.1.13: ‘Consider initiating subcutaneous opioids with 
the lowest acquisition cost for patients in whom oral opioids are not 
suitable and analgesic requirements are unstable, supported by specialist 
advice where needed.’ 
(Fleming, 
2010) 
Patients perceive unstable pain as a sign of deteriorating clinical situation, 
and impending death. 
(Fleming, Patients perceive any increased dose of morphine as leading to sedation 
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Patient’s desire their pain to be controlled so that they can keep their 
usual activities and social relationships. They may prefer pain 
management and methods of administration which can best maintain 
their mobility and independence. 
Table 1: Sample integrative table relating to CG140 
Conclusion 
This paper argues that the positivist framework adopted by CG140 is inappropriate for 
the subject matter. It does not, however, suggest that quantitative research is without 
value. Rather, it highlights some of its weaknesses, unacknowledged within CG140, and 
how it can be complemented with research from alternative philosophies. Much of 
CG140’s reductionist approach to pain management results in disease-centred health 
care, and does not give credence to the experience of the patient. It is important that 
health care professionals do not ignore how pain is experienced and what it means to an 
individual patient. We argue that more space for intuition and alternative philosophical 
approaches would lead to improved patient-centred care, in line with the objectives of 
EBM. 
 
Declaration of Conflicting Interests  
The Authors declare that there is no conflict of interest 
DF is a medical doctor practicing palliative care in West Africa. He is carrying out a mixed-




ARKINSTALL, W. W. et al. (1989). Control of severe pain with sustained-release 
morphine tablets v. oral morphine solution. CMAJ Canadian Medical Association 
Journal, 140, 653-657.  
BERNSTEIN, J. (2016). Restricting Access to Hope: A Parent's Perspective on the NICE 
Preliminary Guidance for Dinutuximab. Pediatric Blood & Cancer, 63(6), 964–965. 
http://doi.org/10.1002/pbc.25949 
BEST, S. (2007). The social construction of pain: an evaluation. Disability & Society, 22, 
161-171. 
BHANDARI, M. et al. (2004). Association between industry funding and statistically 
significant pro-industry findings in medical and surgical randomized trials. CMAJ 
Canadian Medical Association Journal, 170, 477-80. 
BRYMAN, A. (2012). Social research methods. Oxford: Oxford University Press. 
DAVIES, A. et al. (2011). Consistency of efficacy, patient acceptability, and nasal 
tolerability of fentanyl pectin nasal spray compared with immediate-release 
morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage, 41, 358-
66. 
DENG, Y., LUO, L., HIU., Y., FANG, K., & LIU, J. (2016). Clinical practice guidelines for 
the management of neuropathic pain: a systematic review. BMC Anesthesiology, 
16(1), 12. 
ELLINGSON, L. L. (2009). Engaging Crystallization in Qualitative Research. SAGE: 
London 
FLEMMING, K. (2010). The use of morphine to treat cancer-related pain: a synthesis of 
13 
 
quantitative and qualitative research. J Pain Symptom Manage, 39, 139-54. 
GIBBINS, J., BHATIA, R., FORBES, K., & REID, C. M. (2013). What do patients with 
advanced incurable cancer want from the management of their pain? A qualitative 
study. Palliative Medicine, 28(1), 71–78.  
GOLDENBERG, M. J. (2006). On evidence and evidence-based medicine: Lessons from 
the philosophy of science. Social Science & Medicine, 62, 2621-2632. 
GOLDENBERG, M. J. (2014). How can Feminist Theories of Evidence Assist Clinical 
Reasoning and Decision-making? Social Epistemology, 29(1), 3–30. 
GREENHALGH, T., SNOW, R., RYAN, S., REES, S., & SALISBURY, H. (2015). Six 
“biases” against patients and carers in evidence-based medicine. BMC Medicine, 
13(1), 200. 
HARRIS, J. (2005). It's not NICE to discriminate. J Med Ethics, 31, 373-5. 
HAUGEN, D. F., HJERMSTAD, M. J., HAGEN, N., CARACENI, A. & KAASA, S. (2010). 
Assessment and classification of cancer breakthrough pain: a systematic literature 
review. Pain, 149, 476-82. 
HUTCHISON, K. J. & ROGERS, W. A. (2012). Challenging the epistemological 
foundations of EBM: what kind of knowledge does clinical practice require? J Eval 
Clin Pract, 18, 984-91. 
HUNT, N. (2007). Alzheimer's Society replies to Iain Chalmers. British Medical Journal, 
335 (7619), 541. 
KAASA, S. et al. (2011). Expert conference on cancer pain assessment and classification-
-the need for international consensus: working proposals on international 
standards. BMJ Support Palliat Care, 1, 281-7. 
14 
 
KELLY, M. P., HEATH, I., HOWICK, J., & GREENHALGH, T. (2015). The importance of 
values in evidence-based medicine. BMC Medical Ethics, 16(1), 69.  
KOTZEE, B., PATON, A., & CONROY, M. (2016). Towards an Empirically Informed 
Account of Phronesis in Medicine. Perspectives in Biology and Medicine, 59(3), 
337–350.  
MOENS, K., HIGGINSON, I. J. and HARDING, R. (2014). Are there differences in the 
prevalence of palliative care-related problems in people living with advanced cancer and 
eight non-cancer conditions? A systematic review. Journal of Pain and Symptom 
Management, 48(4), 660–677.  
MUNOZ-PLAZA, C. E. et al. (2016). Integrating qualitative research methods into care 
improvement efforts within a learning health system: addressing antibiotic overuse. 
Health Research Policy and Systems, 14(1), 63  
MORRIS, D. (1991). The culture of pain, Berkeley, California, University of California 
Press. 
MORRISSEY, M. B. (2011). Phenomenology of pain and suffering at the end of life: a 
humanistic perspective in gerontological health and social work. J Soc Work End 
Life Palliat Care, 7, 14-38. 
NICE. (2009). The Guidelines Manual 2009 [Online]. London: NICE. Available: 
www.nice.org.uk/media/615/64/The_guidelines_manual_2009.pdf [Accessed 26 
March 2016]. 
NICE. (2012). Opioids in palliative care: safe and effective prescribing of strong opioids 
for pain in palliative care of adults. [CG140] [Online]. London: NICE. Available: 




NICE. (2013). Neuropathic pain in adults: pharmacological management in non-specialist 
settings. [CG173] [Online]. London: NICE. Available:  
www.nice.org.uk/guidance/cg173/chapter/2-List-of-all-research-recommendations 
[Accessed 27 October 2017] 
NICE. (2016). Who we are [Online]. Available:  
www.nice.org.uk/aboutnice/whoweare/who_we_are.jsp [Accessed 17 April 2016]. 
NICE. (2017). Developing NICE guidelines: the manual [Online]. Available:  
www.nice.org.uk/process/pmg20/chapter/reviewing-research-evidence [Accessed 27 
October, 2017] 
NGUYEN, L. M. T. et al. (2013). Frequency and predictors of patient deviation from 
prescribed opioids and barriers to opioid pain management in patients with 
advanced cancer. Journal of Pain and Symptom Management, 45(3), 506–516. 
RENQVIST, A.L. (2015). An Apology for Pain. Comparative and Continental Philosophy, 
4(2), 179–193. 
ROGERS, W. & BALLANTYNE, A. (2009). Justice in health research: What is the role of 
evidence-based medicine? Perspect Biol Med, 52, 188-202. 
SACKETT, D. L., ROSENBERG, W. M., GRAY, J. A., HAYNES, R. B. & RICHARDSON, 
W. S. (1996). Evidence based medicine: what it is and what it isn't. BMJ, 312, 71-
2. 
SCHILD von SPANNENBERG, S., JONES, G. T., & MACFARLANE, G. J. (2013). The 




STREETER, E. H. and BREWSTER, S. F., (2015). NICE guidelines on Prostate Cancer 
Active Surveillance: is UK practice leading the world? British Journal of Urology 
International, 115(1), 12–13. 
SVENAEUS, F. (2003). Hermeneutics of medicine in the wake of Gadamer: the issue of 
phronesis. Theor Med Bioeth, 24, 407-31. 
UTENS, C. M. A., DIRKSEN, C. D., van der WEIJDEN, T., & JOORE, M. A. (2016). How 
to integrate research evidence on patient preferences in pharmaceutical coverage 
decisions and clinical practice guidelines: A qualitative study among Dutch 
stakeholders. Health Policy (Amsterdam, Netherlands), 120(1), 120–128.  
WATTS, P., & SMITH, A. (2009). PecSys: in situ gelling system for optimised nasal drug 
delivery. Expert Opinion on Drug Delivery, 6(5), 543–552. 
WILMOT, S. (2011). Evidence, ethics and inclusion: a broader base for NICE. Med Health 
Care Philos, 14, 111-21. 
WORLD HEALTH ORGANISATION (n.d.). WHO’s pain relief ladder [Online]. Available: 
http://www.who.int/cancer/palliative/painladder/en/ [Accessed 15 April 2016]. 
 
 
